DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Return
12.76%
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$332M
(+6.1%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-14.52%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
65
Reduced
45
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Consolidated Edison
ED
$35.4B
| $297K | 0.01% |
+3,275
| New | +$297K |
|
252
Group 1 Automotive
GPI
$6.26B
| $294K | 0.01% |
+1,007
| New | +$294K |
|
253
Calavo Growers
CVGW
$485M
| $294K | 0.01% |
+10,574
| New | +$294K |
|
254
Freshworks
FRSH
$3.74B
| $292K | 0.01% |
+16,036
| New | +$292K |
|
255
Corteva
CTVA
$49.1B
| $292K | 0.01% |
+5,058
| New | +$292K |
|
256
Bristol-Myers Squibb
BMY
$96B
| $291K | 0.01% |
5,370
-2,892
| -35% | -$157K |
|
257
Old Republic International
ORI
$10.1B
| $290K | 0.01% |
+9,447
| New | +$290K |
|
258
Ocular Therapeutix
OCUL
$2.37B
| $290K | 0.01% |
31,852
+12,865
| +68% | +$117K |
|
259
Tiptree Inc
TIPT
$849M
| $289K | 0.01% |
+16,728
| New | +$289K |
|
260
Travelers Companies
TRV
$62B
| $288K | 0.01% |
+1,251
| New | +$288K |
|
261
Quest Diagnostics
DGX
$20.5B
| $287K | 0.01% |
+2,157
| New | +$287K |
|
262
The Beauty Health Co
SKIN
$260M
| $283K | ﹤0.01% |
63,835
+48,678
| +321% | +$216K |
|
263
Harmony Biosciences
HRMY
$2.07B
| $283K | ﹤0.01% |
+8,420
| New | +$283K |
|
264
AMERISAFE
AMSF
$871M
| $283K | ﹤0.01% |
+5,633
| New | +$283K |
|
265
4D Molecular Therapeutics
FDMT
$340M
| $281K | ﹤0.01% |
+8,821
| New | +$281K |
|
266
Janus International
JBI
$1.44B
| $280K | ﹤0.01% |
18,539
-3,422
| -16% | -$51.8K |
|
267
iHeartMedia
IHRT
$315M
| $275K | ﹤0.01% |
131,552
+18,301
| +16% | +$38.2K |
|
268
Confluent
CFLT
$6.67B
| $274K | ﹤0.01% |
+8,962
| New | +$274K |
|
269
AngioDynamics
ANGO
$436M
| $273K | ﹤0.01% |
46,591
+31,239
| +203% | +$183K |
|
270
Omnicell
OMCL
$1.47B
| $272K | ﹤0.01% |
+9,300
| New | +$272K |
|
271
Liquidia Corp
LQDA
$2.48B
| $272K | ﹤0.01% |
+18,429
| New | +$272K |
|
272
Veeva Systems
VEEV
$44.7B
| $272K | ﹤0.01% |
+1,172
| New | +$272K |
|
273
Absci
ABSI
$368M
| $269K | ﹤0.01% |
+47,441
| New | +$269K |
|
274
W.R. Berkley
WRB
$27.3B
| $269K | ﹤0.01% |
+4,568
| New | +$269K |
|
|
275
Baxter International
BAX
$12.5B
| $262K | ﹤0.01% |
6,141
-1,352,545
| -100% | -$57.8M |
|